MicroRNA miR-146b-5p regulates signal transduction of TGF-Β by repressing SMAD4 in thyroid cancer

Oncogene

Volumn 31, Issue 15, 2012, Pages 1910-1922

  Geraldo, M V ^a   Yamashita, A S ^a   Kimura, E T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

microRNA; papillary thyroid carcinoma; TGF

Indexed keywords

MICRORNA; MIR 146B 5P; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE; GENE REPRESSION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE RET; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SMAD 4 GENE; THYROID PAPILLARY CARCINOMA;

3' UNTRANSLATED REGIONS; ANIMALS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; ONCOGENES; RATS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; THYROID GLAND; THYROID NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

RATTUS;

EID: 84859746790     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.381     Document Type: Article

References (53)

1. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ et al. (2006). Correlation between genetic alterations and microscopicfeatures, clinical manifestations, and prognostic characteristicsof thyroid papillary carcinomas. Am J Surg Pathol 30:216-222. (Pubitemid 43740191)
2. Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, andfunction. Cell 116: 281-297.
3. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC.(2008). Expression of microRNA-146 suppresses NF-kappaBactivity with reduction of metastatic potential in breast cancer cells.Oncogene 27: 5643-5647.
4. Cahill S, Smyth P, Finn SP, Denning K, Flavin R, O'Regan EM et al.(2006). Effect of ret/PTC 1 rearrangement on transcription andpost-transcriptional regulation in a papillary thyroid carcinomamodel. Mol Cancer 5: 70.
5. Calin GA, Croce CM. (2006). MicroRNA signatures in humancancers. Nat Rev Cancer 6: 857-866.
6. Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM, Kimura ET. (2003). Expression of Smad4 and Smad7 in humanthyroid follicular carcinoma cell lines. J Endocrinol Invest 26:516-521. (Pubitemid 36998699)
7. Chou CK, Chen RF, Chou FF, Chang HW, Chen YJ, Lee YF et al. (2010). miR-146b is highly expressed in adult papillarythyroid carcinomas with high risk features including extrathyroidalinvasion and the BRAF(V600E) mutation. Thyroid 20:489-494.
8. Costamagna E, Garcia B, Santisteban P. (2004). The functionalinteraction between the paired domain transcription factorPax8 and Smad3 is involved in transforming growth factor-betarepression of the sodium/iodide symporter gene. J Biol Chem 279:3439-3446. (Pubitemid 38140582)
9. D'Inzeo S, Nicolussi A, Ricci A, Mancini P, Porcellini A, Nardi F et al. (2010). Role of reduced expression of SMAD4 in papillarythyroid carcinoma. J Mol Endocrinol 45: 229-244.
10. Dykxhoorn DM. (2010). MicroRNAs and metastasis: little RNAs go along way. Cancer Res 70: 6401-6406.
11. Ellenrieder V. (2008). TGFbeta regulated gene expression by Smadsand Sp1/KLF-like transcription factors in cancer. Anticancer Res28: 1531-1539. (Pubitemid 351892926)
12. Ermak G, Cancasci VJ, Davies KJ. (2003). Cytotoxic effect ofdoxycycline and its implications for tet-on gene expression systems.Anal Biochem 318: 152-154. (Pubitemid 36627495)
13. Fabien N, Fusco A, Santoro M, Barbier Y, Dubois PM, Paulin C(1994). Description of a human papillary thyroid carcinoma cellline. Morphologic study and expression of tumoral markers. Cancer73: 2206-2212.
14. Fagin JA. (2002). Minireview: branded from the start-distinctoncogenic initiating events may determine tumor fate in the thyroid.Mol Endocrinol 16: 903-911. (Pubitemid 34478529)
15. Franzen A, Piek E, Westermark B, ten Dijke P, Heldin NE. (1999).Expression of transforming growth factor-beta1, activin A, andtheir receptors in thyroid follicle cells: negative regulation ofthyrocyte growth and function. Endocrinology 140: 4300-4310. (Pubitemid 30647129)
16. Fusco A, Berlingieri MT, Di Fiore PP, Portella G, Grieco M, Vecchio G. (1987). One-and two-step transformations of ratthyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 7:3365-3370.
17. Garcia-Jimenez C, Santisteban P. (2007). TSH signalling and cancer.Arq Bras Endocrinol Metabol 51: 654-671.
18. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al.(2005). The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080. (Pubitemid 43049568)
19. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV et al. (1998). Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367. (Pubitemid 28295292)
20. Heldin CH, Landstrom M, Moustakas A. (2009). Mechanism of TGFbetasignaling to growth arrest, apoptosis, and epithelial- mesenchymaltransition. Curr Opin Cell Biol 21: 166-176.
21. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, WelchDR. (2009). Breast cancer metastasis suppressor 1 up-regulatesmiR-146, which suppresses breast cancer metastasis. Cancer Res 69:1279-1283.
22. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010.CA Cancer J Clin 60: 277-300.
23. Jhiang SM, Caruso DR, Gilmore E, Ishizaka Y, Tahira T, Nagao Met al. (1992). Detection of the PTC/retTPC oncogene in humanthyroid cancers. Oncogene 7: 1331-1337.
24. Kawaguchi A, Ikeda M, Endo T, Kogai T, Miyazaki A, Onaya T.(1997). Transforming growth factor-beta1 suppresses thyrotropininducedNa +I-symporter messenger RNA and protein levels inFRTL-5 rat thyroid cells. Thyroid 7: 789-794. (Pubitemid 28086214)
25. Kimura ET, Kopp P, Zbaeren J, Asmis LM, Ruchti C, Maciel RMet al. (1999). Expression of transforming growth factor beta1, beta2, and beta3 in multinodular goiters and differentiated thyroidcarcinomas: a comparative study. Thyroid 9: 119-125. (Pubitemid 29115531)
26. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, FaginJA. (2003). High prevalence of BRAF mutations in thyroid cancer:genetic evidence for constitutive activation of the RET/PTC-RASBRAFsignaling pathway in papillary thyroid carcinoma. CancerRes 63: 1454-1457. (Pubitemid 36373628)
27. Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-Costantini R et al. (2005). A complex pattern of mutations andabnormal splicing of Smad4 is present in thyroid tumours. Oncogene24: 5344-5354. (Pubitemid 43080104)
28. Massague J. (1998). TGF-beta signal transduction. Annu Rev Biochem67: 753-791.
29. Massague J. (2008). TGFbeta in cancer. Cell 134: 215-230.
30. Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Friguglietti CU, Ferro MC et al. (2010). Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arq BrasEndocrinol Metabol 54: 406-412.
31. Matsuo SE, Leoni SG, Colquhoun A, Kimura ET. (2006). Transforminggrowth factor-beta1 and activin A generate antiproliferativesignaling in thyroid cancer cells. J Endocrinol 190: 141-150. (Pubitemid 44161069)
32. Morris III JC, Ranganathan G, Hay ID, Nelson RE, Jiang NS. (1988).The effects of transforming growth factor-beta on growth anddifferentiation of the continuous rat thyroid follicular cell line, FRTL-5. Endocrinology 123: 1385-1394.
33. Moustakas A, Heldin CH. (2005). Non-Smad TGF-beta signals. J CellSci 118: 3573-3584.
34. Nicolussi A, D'Inzeo S, Santulli M, Colletta G, Coppa A. (2003).TGF-beta control of rat thyroid follicular cells differentiation. MolCell Endocrinol 207: 1-11. (Pubitemid 37102948)
35. Nikiforova MN, Chiosea SI, Nikiforov YE. (2009). MicroRNAexpression profiles in thyroid tumors. Endocr Pathol 20: 85-91.
36. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE.(2008). MicroRNA expression profiling of thyroid tumors: biologicalsignificance and diagnostic utility. J Clin Endocrinol Metab 93:1600-1608. (Pubitemid 351656494)
37. Pacifico F, Crescenzi E, Mellone S, Iannetti A, Porrino N, Liguoro Det al. (2010). Nuclear factor-\{kappa\}B contributes to anaplasticthyroid carcinomas through up-regulation of. J Clin EndocrinolMetab 95: 1421-1430.
38. Paire A, Bernier-Valentin F, Selmi-Ruby S, Rousset B. (1997).Characterization of the rat thyroid iodide transporter using antipeptideantibodies. Relationship between its expression and activity.J Biol Chem 272: 18245-18249. (Pubitemid 27306413)
39. Pallante P, Visone R, Croce CM, Fusco A. (2010). Deregulation ofmicroRNA expression in follicular-cell-derived human thyroidcarcinomas. Endocr Relat Cancer 17: F91-104.
40. Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, SedliarouI et al. (2006). BRAFV600E promotes invasiveness of thyroidcancer cells through nuclear factor kappaB activation. Endocrinology 147: 5699-5707. (Pubitemid 44833486)
41. Pei XH, Xiong Y. (2005). Biochemical and cellular mechanisms ofmammalian CDK inhibitors: a few unresolved issues. Oncogene 24:2787-2795. (Pubitemid 40638090)
42. Pfaffl MW. (2001). A new mathematical model for relative quantificationin real-time RT-PCR. Nucleic Acids Res 29: e45.
43. Ricarte-Filho JC, Fuziwara CS, Yamashita AS, Rezende E, da-Silva MJ, Kimura ET. (2009). Effects of let-7 microRNA on cell growth anddifferentiation of papillary thyroid cancer. Transl Oncol 2: 236-241.
44. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M et al. (2009). The BRAFV600E oncogeneinduces transforming growth factor beta secretion leading to sodiumiodide symporter repression and increased malignancy in thyroidcancer. Cancer Res 69: 8317-8325.
45. Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R et al. (2000). The RAS oncogene induces genomicinstability in thyroid PCCL3 cells via the MAPK pathway.Oncogene 19: 3948-3954. (Pubitemid 30658985)
46. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G. (2002).Molecular mechanisms of RET activation in human cancer. Ann NYAcad Sci 963: 116-121. (Pubitemid 34721703)
47. Siegel PM, Massague J. (2003). Cytostatic and apoptotic actions ofTGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
48. Taganov KD, Boldin MP, Chang KJ, Baltimore D. (2006). NFkappaB-dependent induction of microRNA miR-146, an inhibitortargeted to signaling proteins of innate immune responses. Proc NatlAcad Sci USA 103: 12481-12486. (Pubitemid 44267285)
49. Taton M, Lamy F, Roger PP, Dumont JE. (1993). General inhibitionby transforming growth factor beta 1 of thyrotropin and cAMPresponses in human thyroid cells in primary culture. Mol CellEndocrinol 95: 13-21. (Pubitemid 23267191)
50. Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M et al.(2003). Conditional expression of RET/PTC induces a weakoncogenic drive in thyroid PCCL3 cells and inhibits thyrotropinaction at multiple levels. Mol Endocrinol 17: 1425-1436. (Pubitemid 36819961)
51. Xia H, Qi Y, Ng SS, Chen X, Li D, Chen S et al. (2009). microRNA-146b inhibits glioma cell migration and invasion by targetingMMPs. Brain Res 1269: 158-165.
52. Yang G, Yang X. (2010). Smad4-mediated TGF-beta signaling intumorigenesis. Int J Biol Sci 6: 1-8.
53. Zhong H, Wang HR, Yang S, Zhong JH, Wang T, Wang C et al.(2010). Targeting Smad4 links microRNA-146a to the TGF-betapathway during retinoid acid induction in acute promyelocyticleukemia cell line. Int J Hematol 92: 129-135.